Adkins D, Ley JC, Wildes TM, Michel LS, Rich J, Paniello R, Uppaluri R, Thorstad WL, Gay HA, Trinkaus K, Rachocki T, Nussenbaum B. The role of cetuximab in induction chemotherapy: Comparison of APF-C (nab-paclitaxel, cisplatin, 5-FU + cetuximab) with APF, both followed by chemoradiation therapy (CRT), in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.6042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Ley JC, Nussenbaum B, Diaz J, Rich J, Paniello R, Uppaluri R, Thorstad WL, Gay HA, Rachocki T, Varges J, Wildes TM, Michel LS, Adkins D. Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.6013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Adkins D, Ley J, Nussenbaum B, Diaz J, Paniello R, Thorstad WL, Gay HA, Subramanian J, Wildes TM, Mathai J, Rachocki T, Kuperman DI. Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5560] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Kuperman DI, Ley J, Nussenbaum B, Diaz J, Paniello R, Thorstad WL, Gay HA, Subramanian J, Wildes TM, Mathai J, Rachocki T, Adkins D. Safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Ley J, Siegel BA, Dehdashti F, Subramanian J, Ansstas G, Rachocki T, Mathai J, Wildes TM, Kuperman DI, Adkins D. Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Kuperman DI, Ley J, Nussenbaum B, Gay H, Thorstad WL, Rachocki T, Subramanian J, Adkins D. Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e16028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Ley J, Adkins D, Kuperman D, Siegel B, Dehdashti F, Wippold F, Trinkaus K, Subramanian J, Rachocki T. Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Van Tine BA, Ley J, Nussenbaum B, Thorstad WL, Gay H, Rachocki T, Subramanian J, Kuperman DI, Adkins D. Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open

Mosley JC, Ganz B, Rachocki T, Ley J, Seckfort D, Morgensztern D, Kuperman DI, Adkins DR. Efficacy of cetuximab-based second-line therapy in patients with metastatic head and neck squamous cell carcinoma (HNSCC) which progressed on gefitinib-based first-line therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open